SUNNYVALE, Calif.--(BUSINESS WIRE)--Aptus Endosystems, Inc., a medical device company pioneering solutions to enhance aneurysm repair, today announced that it has appointed Ruth Lyons to the position of Vice President, Global Marketing. Ms. Lyons will lead all global marketing activities and drive business strategy development and execution. Ms. Lyons has more than 25 years in medical device marketing with industry-leading companies and innovative, market-changing products.
Ms. Lyons comes to Aptus with a wealth of experience in cardiac-related clinical specialties. She has held senior marketing and sales roles with Baxter Healthcare and Johnson & Johnson. In the position of Vice President, Strategic Marketing and Product Planning at St. Jude Medical Inc., she made significant contributions leading to a period of exceptional revenue growth and market share gain. She continued to expand her expertise in the vascular surgery market, and specifically in endovascular aortic aneurysm repair (EVAR), in her most recent role as Vice President, Global Marketing for Endologix.
“We’re very pleased to welcome Ms. Lyons to the Aptus management team,” said James Reinstein, President and Chief Executive Officer of Aptus Endosystems. “As we continue to gain traction in the market with plans to strategically expand our portfolio, Ms. Lyons’ years of experience in the medical device industry and specifically within the EVAR and vascular surgery space will be invaluable to building the company’s growth and profitability.”
Ms. Lyons received a Bachelor of Science degree in Business Administration from California State University. She continued her studies at the University of Southern California, where she received a Masters of Business Administration.
About Aptus Endosystems, Inc.
Aptus Endosystems is a privately held, Sunnyvale, California-based medical device company that is pioneering solutions to enhance aneurysm repair. Aptus is focused on improving long-term outcomes and quality of life for patients undergoing EVAR and TEVAR procedures. Aptus has developed a unique helical anchor technology that locks the endograft to the aorta to address long-term durability. Aptus has successfully designed and brought to market two endograft anchoring systems that are currently being used in EVAR and TEVAR procedures in the United States and Europe—the Heli-FX EndoAnchor System and the Heli-FX Thoracic EndoAnchor System. For more information, please visit www.aptusendo.com.
